14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MGN vs ABEO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Megan Holdings Limited (MGN) is the stronger overall head-to-head candidate over Abeona Therapeutics Inc. (ABEO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MGN carries a Unified Composite Score of 45.2/100 (HOLD) at $3.53 (N/M Forward P/E, -7.8% operating margin), whereas ABEO carries 44.9/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin).
Growth vs. Quality Trade-Off: MGN earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. ABEO 44.9/100 HOLD) and 21.11β · 158% Vol risk profile, whereas ABEO leads top-line expansion (+2745.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: MGN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.2); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MGN vs ABEO. Trailing 12-month operating profitability (MGN -7.8% vs ABEO -186.1%) and valuation multiples (MGN N/M vs ABEO 18.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $149.2M market capitalization and -186.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MGN vs ABEO Key Questions & Quantitative Answers
As of Nov 16, 2026, Megan Holdings Limited (MGN) is the stronger overall head-to-head candidate over Abeona Therapeutics Inc. (ABEO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MGN carries a Unified Composite Score of 45.2/100 (HOLD) at $3.53 (N/M Forward P/E, -7.8% operating margin), whereas ABEO carries 44.9/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin). Growth vs. Quality Trade-Off: MGN earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. ABEO 44.9/100 HOLD) and 21.11β · 158% Vol risk profile, whereas ABEO leads top-line expansion (+2745.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MGN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.2); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABEO leads the Growth & Scale pillar: MGN posts -8.4% YoY revenue growth and -31.3% YoY earnings growth on $83M TTM revenue (0.8% gross margin, -7.8% operating margin), compared with ABEO at +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin). On trailing 12-month operating scale, MGN generates $83M in USD-normalized revenue versus $39M for ABEO. In operating R&D and SG&A reinvestment, MGN deploys 8.6% of Rev ($7.1M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABEO.
ABEO screens cheaper on headline valuation multiples. MGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-7.7% EBITDA margin), whereas ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MGN (-12.6% ROE) versus ABEO (-42.1% ROE) capital efficiency.
In options market volatility and institutional positioning, MGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (21.11β · 158% Vol realized risk). By comparison, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.